GH Jan 2025 35.000 call
| Previous close | 2.8500 |
| Open | 2.2000 |
| Bid | 2.6000 |
| Ask | 3.0000 |
| Strike | 35.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.2000 - 2.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 94 |
Investor's Business DailyGuardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood Tests
Guardant Health stock jumped Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.
Barrons.comGuardant Health Stock Jumps. Blood Test for Cancer Moves Toward FDA Approval.
Shares of Guardant Health were rising sharply after the cancer company said a Food and Drug Administration advisory committee recommended the agency approve the company’s blood test for colorectal cancer screening. The test, Shield, is for people 45 and older who are at average risk for the disease, according to the release. “The recommendation signals the advisory committee panel’s consensus on Shield’s safety and effectiveness with its proposed intended use, and their conclusion that its benefits as a primary non-invasive screening option outweigh any potential risks,” according to the release.
Business WireFDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
PALO ALTO, Calif., May 23, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA)’s Medical Devices Advisory Committee has strongly recommended FDA approval of the company’s Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
